Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)

Phase 1/2 Active not recruiting 9 enrolled West China Hospital

Non-randomizedSequentialSingle-blindTreatment

Summary

The purpose of the study is to assess the safety and efficacy of JWK006 in Stargardt Disease(STGD1). JWK006 is packed by adeno-associated virus vector that expressing ABCA4 gene.

Timeline

Start: 2023-11-20
Primary completion: 2026-12-30
Completion: 2029-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JWK006	Unknown	—	Other

Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)

Summary

Timeline

Drugs

Indications